MedWatch

US health authority reprimands large pharmaceutical firms after disagreement on drug discounts

Earlier in the week, the US HRSA sent a letter to many of the largest companies in the pharmaceutical industry concerning their approach to the 340B program which aims to ensure that hospitals get drug discounts.

Photo: Mike Segar/Reuters/Ritzau Scanpix

The US Department of Health & Human Services (HHS) is cracking down on many of the largest players in the pharmaceutical industry according to healthcare media Endpoints.

Endpoints notes that the Health Resources and Services Administration (HRSA) Acting Administrator Diana Espinosa has sent out a letter to major pharmaceutical companies such as Novo Nordisk, Sanofi, Astrazeneca, Eli Lilly, Novartis and United Therapeutics on Monday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs